Page 149 - 2019_04-Haematologica-web

TIRAP, a novel familial lymphoma risk gene
an adapter molecule in the Toll signaling
pathway. Nat Immunol. 2001;2(9):835–841.
21. Li H. Toward better understanding of arti- facts in variant calling from high-coverage samples. Bioinformatics. 2014;30(20):2843-
2851.
22. Ritz O, Guiter C, Castellano F, et al.
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B- cell lymphoma. Blood. 2009;114(6):1236- 1242.
23. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 am-plification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lym- phoma. Blood. 2010;116(17):3268-3277.
24. Mottok A, Woolcock B, Chan FC, et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep. 2015;13(7):1418-1431.
25. Challa-Malladi M, Lieu YK, Califano O, et al. Combined Genetic Inactivation of Beta2- Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B-cell Lymphoma. Cancer Cell. 2011;20(6):728-740.
26. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic signifi- cance of TP53 in diffuse large B-cell lym- phoma patients treated with R-CHOP: report from an In-ternational DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986-3996.
27. Valera A, López-Guillermo A, Cardesa- Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lym-phoma treated with immunochemotherapy. Haematologica. 2013;98(10):1554-1562.
28. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recur- rent gene fusion partner in lymphoid can- cers. Nature. 2011;471(7338):377-381.
29. Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lym- phoma. Blood. 2015;126(19):2193-2201.
30. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma
of germinal center origin with BCL2 translo- cations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Pro- gram Study. Haematologica. 2013;98(2): 255-263.
31. Cancer data extracted from the Swiss national dataset managed by the Fondation Na-tional Institute for Cancer Epidemiology and Registration (NICER). Available from: http://www.nicer.org/. Accessed on February 2015. http://www.nicer.org/ de/[Last accessed September 15, 2016].
32. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
33. Bonetti P, Testoni M, Scandurra M, et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood. 2013;122(13):2233- 2241.
34. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lym-phoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
35. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407.
36. Richards S, Aziz N, Bale S, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
37. Higasa K, Miyake N, Yoshimura J, et al. Human genetic variation database, a refer- ence database of genetic variations in the Japanese population. J Hum Genet. 2016; 61(6):547-553.
38. Caraux A, Klein B, Paiva B, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characteriza- tion of circulating normal CD138− and CD138+ plasma cells. Haematologica. 2010;95(6):1016-1020.
39. Chong Y, Ikematsu H, Yamaji K, et al. CD27(+) (memory) B cell decrease and apopto-sis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol. 2005;17(4):383- 390.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and de-regulation of the JAK2-STAT cas- cade in lymphomas. Mod Pathol. 2009; 22(3):476-487.
Nocturne G, Boudaoud S, Miceli-Richard C, et al. Germline and somatic genetic varia- tions of TNFAIP3 in lymphoma complicat- ing primary Sjögren’s syndrome. Blood. 2013;122(25):4068-4076.
Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by nov-el germline CARD11 mutations. J Exp Med. 2012;209(12):2247-2261.
Yang Y, Schmitz R, Mitala J, et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov. 2014;4(4):480-493.
Valkov E, Stamp A, DiMaio F, et al. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci. 2011;108(36):14879- 14884.
Lin Z, Lu J, Zhou W, Shen Y. Structural Insights into TIR Domain Specificity of the Bridging Adaptor Mal in TLR4 Signaling. PloS One. 2012;7(4):e34202.
Bernuth H von, Picard C, Jin Z, et al. Pyogenic Bacterial Infections in Humans with MyD88 Deficiency. Science. 2008; 321(5889):691-696.
Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, et al. SurvExpress: an online biomarker validation tool and data- base for cancer gene expression data using survival analysis. PloS One. 2013;8(9):e74250.
Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212(13):2189- 2201.
Miranda NFCC de, Georgiou K, Chen L, et al. Exome sequencing reveals novel muta- tion targets in diffuse large B-cell lym- phomas derived from Chinese patients. Blood. 2014;124(16):2544-2553.
Juilland M, Gonzalez M, Erdmann T, et al. CARMA1- and MyD88-dependent activa- tion of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lym- phomas. Blood. 2016;127(14):1780-1789.
haematologica | 2019; 104(4)
777